Table 5.

Incidence of bleeding according to the idiopathic pulmonary fibrosis treatment group

	IPF treatment
	Pirfenidone	Nintedanib	Other
Patients, n (PY at risk)
Group A	589 (549.3)	465 (312.5)	774 (579.9)
Group B	86 (111.5)	31 (25.3)	110 (97.4)
Group C	220 (225.9)	161 (166.6)	278 (271.9)
Group D	38 (63.2)	16 (16.1)	26 (26.2)
Total	933 (1123.6)	673 (514.7)	1188 (975.5)
Number of bleeding events (% of all bleeding events)
Group A	0 (0.0)	5 (62.5)	0 (0.0)
Group B	0 (0.0)	0 (0.0)	0 (0.0)
Group C	0 (0.0)	1 (12.5)	0 (0.0)
Group D	1 (12.5)	1 (12.5)	0 (0.0)
Total	1 (12.5)	7 (87.5)	0 (0.0)
Incidence of bleeding
Rate/10,000 PY, total (95% CI)	8.9 (1.3–63.0)	136.9 (65.2–287.1)	–
Relative incidence ratio nintedanib: pirfenidone (95% CI)	15.4 (2.0–695.3) P < 0.001

CI confidence interval, IPF idiopathic pulmonary fibrosis, PY patient-years